CHINESE ACADEMY of MEDICAL SCIENCES OXFORD INSTITUTE

NUFFIELD DEPARTMENT of MEDICINE

UNIVERSITY OF OXFORD

CAMS OXFORD INSTITUTE
HEALTHY AGEING SYMPOSIUM

BIOGRAPHIES OF CAMS PUMC

- 11th June 2026, Oxford -

CAMS Oxford Institute Healthy Ageing Symposium

11th June 2026, Sultan Nazrin Shah Centre, Worcester College, University of Oxford, Walton St, Oxford, OX1 2HB

08: 30 - 09: 00	**Delegate Registration**			
	Opening Remarks	***Chairs:***	*Prof. Tao Dong*	FMedSci, Co-Director of CAMS Oxford Institute, Ita Askonas Professor of Translational Immunology, University of Oxford
09: 00 - 09: 05	Opening Remarks		*Prof. Richard Cornall*	FMedSci, Head of Nuffield Department of Medicine, Nuffield Professor of Clinical Medicine, University of Oxford
09: 05 - 09: 10			*Prof. Xunming Ji*	Member of CAE, President of CAMS PUMC, Professor of CAMS PUMC
09: 10 - 09: 15			*Prof. Shuyang Zhang*	Vice President of CAMS PUMC, President of Peking Union Medical College Hospital, Professor of CAMS PUMC
09: 15 - 09: 20			*Mr. Mingqin Ding*	Minister Counsellor for Science and Technology Affairs, Chinese Embassy in the UK
	Keynotes	***Chairs:***	*Sir. Andrew McMichael*	FRS, Professor of Molecular Medicine, University of Oxford
			Prof. Tao Cheng	Member of CAE, President of Institute of Hematology & Blood Diseases Hospital, Professor of CAMS PUMC
09: 20 - 09: 50	Redox Rhythms Promote Fitness by Modulating Ageing-dependent Reprograming		*Prof. Depei Liu*	Member of CAE, Professor of CAMS PUMC
09: 50 - 10: 20	Behavioural and Social Determinants of Ageing		*Prof. Sarah Harper*	CBE, FMedSci, Director of Oxford Institute of Population Ageing, Clore Professor of Gerontology, University of Oxford
10: 20 - 10: 50	Dissecting the Blood Ecosystem in Steady State and Diseases		*Prof. Tao Cheng*	Member of CAE, President of IHBDH, Professor of CAMS PUMC
10: 50 - 11: 20	**Refreshment Break**			
	Scientific Session - 1	**Chairs:**	*Prof. Douglas Higgs*	FRS, Emeritus Professor, University of Oxford
			Prof. Zhuang Tian	Director of International Medical Services, PUMC Hospital, Professor of CAMS PUMC
11: 20 - 11: 40	Vaccines - what next?		*Prof. Teresa Lambe*	OBE, FMedSci, Calleva Head of Vaccine Immunology, Professor of Vaccinology & Immunology, University of Oxford
11: 40 - 12: 00	Chinese Wisdom in Addressing Cardiovascular Disease and Aging: Percutaneous and Non-Fluoroscopic procedure		*Prof. Xiangbin Pan*	Vice President of Fuwai Hospital, Professor of CAMS PUMC
12: 00 - 12: 20	Crossing Disciplines in Cardiovascular Sciences		*Prof. Keith Channon*	FMedSci, FRCP, Head of Radcliffe Department of Medicine, Field Marshal Earl Alexander Professor of Cardiovascular Medicine, University of Oxford
12: 20 - 12: 40	Molecular Classification for Precise Managements of Esophageal Cancer Patients		*Prof. Zhihua Liu*	Vice President of Cancer Hospital, Professor of CAMS PUMC
12: 40 - 14: 00	**Lunch Break**			
	Remarks	**Chair:**	*Prof. David Stuart*	FRS, Co-Head of STRUBI, Professor of Structural Biology, University of Oxford
14: 00 - 14: 10	Remarks from VC of the University of Oxford		*Prof. Irene Tracey*	Vice-Chancellor of the University of Oxford, CBE, FRS, FMedSci, Professor of Anesthetic Neuroscience, Nuffield Department of Clinical Neurosciences, University of Oxford
14: 10 - 14: 20	**Group Photo**			
	Scientific Session - 2	**Chairs:**	*Prof. David Stuart*	FRS, Co-Head of STRUBI, Professor of Structural Biology, University of Oxford
			Prof. Zhongjie Li	Executive Vice Dean of the School of Population Medicine and Public Health, Professor of CAMS PUMC
14: 20 - 14: 40	Discovery to Innovation Strategy at Kennedy Institute of Rheumatology		*Prof. Michael Dustin*	FRS, Kennedy Trust Professor of Molecular Immunology, Kennedy Institute of Rheumatology, NDORMS, University of Oxford
14: 40 - 15: 00	Research on the Pathogenic Mechanism of Influenza Virus Infection		*Prof. Yuelong Shu*	Director of Institute of Pathogen Biology, Professor of CAMS PUMC
15: 00 - 15: 20	Shingles Vaccination and Dementia: A Natural Experiment		*Prof. Maxime Taquet*	Associate Professor, Department of Psychiatry, University of Oxford
15: 20 - 15: 40	Influenza Virus Antigenic Evolution Analysis and Mucosal Vaccine Development		*Prof. Youchun Wang*	Director of Institute of Medical Biology, Professor of CAMS PUMC
15: 40 - 16: 00	**Refresement Break**			
	Scientific Session - 3	**Chairs:**	*Prof. Graham Ogg*	FMedSci, Professor of Dermatology, University Of Oxford
			Prof. Xuemei Li	Director of the Department of Internal Medicine, PUMC Hospital, Professor of CAMS PUMC
16: 00 - 16: 20	Intelligent Assessment and Management of Sarcopenia in Older Adults		*Prof. Lin Kang*	Director of Geriatrics Department, PUMC Hospital, Professor of CAMS PUMC
16: 20 - 16: 40	Infection and Multimorbidity in the Context of Aging		*Prof. Zhongjie Li*	Executive Vice Dean of the School of Population Medicine and Public Health, Professor of CAMS PUMC
16: 40 - 17: 00	Primary Care and its central role in Multiple Long Term Conditions		*Sir. Aziz Sheikh*	OBE, FRSE, FMedSci , Pro-Vice-Chancellor, Head of Nuffield Department of Primary Care Health Sciences, Professor of University of Oxford
17: 00 - 17: 10	**Closing Remarks**		*Prof. Tao Dong*	FMedSci, Co-Director of CAMS Oxford Institute, Ita Askonas Professor of Translational Immunology, University of Oxford
17: 30 - 21: 30	**Networking Reception & Welcome Dinner**			Venue: Life & Mind Building, South Parks Road, University of Oxford

Speaker biographies are presented in programme order.

XUNMING JI

Professor
President of CAMS PUMC
Academician of the Chinese Academy of Engineering

Prof. Xunming Ji is a neurologist and an Academician of the Chinese Academy of Engineering. He is a Member of the Academic Advisory Committee of the Chinese Academy of Medical Sciences and is recognized as a National Leading Talent in Science and Technology Innovation and a Beijing Scholar. Currently, he serves as President of Chinese Academy of Medical Sciences & Peking Union Medical College, Director of the Beijing Institute for Brain Disorders, and Director of the Stroke Center at Xuanwu Hospital. He is also Chair of the National Expert Group for Active Health and Aging, Chair of the Expert Committee for the stroke prevention project of National Health Commission, Chair of the China Healthy Aging Promotion Project Expert Committee, and Director of the National Engineering Research Center for Internet Healthcare Diagnosis and Treatment Technology.

Prof. Ji has long been engaged in research on the pathogenesis and the diagnostics and therapeutics of arterial and venous stroke. He identified a novel neuroprotective mechanism involving intercellular mitochondrial transfer, developed new strategies for neuroprotection in stroke, and pioneered three groundbreaking neuroprotective techniques: Remote Ischemic Conditioning (RIC), Normobaric Hyperoxia (NBO), and Targeted Therapeutic Hypothermia (RTH). His seminal work on cerebral venous thrombosis, stenosis, and tinnitus has been incorporated into internationally recognized textbooks, improving outcomes for thousands of patients with complex neurological conditions.

Prof. Ji has published as corresponding author in top-tier international journals such as Nature, The Lancet, and The New England Journal of Medicine. He has been recognized as one of China's Highly Cited Researchers by Elsevier for seven consecutive years.

His contributions have been honored with notable awards, including two Second Prizes of the National Science and Technology Progress Award, five First-Class Ministerial or Provincial-level Science and Technology Progress Awards, the National Excellence and Innovation Award, the Ho Leung Ho Lee Foundation Science and Technology Progress Award, and the Wu Jieping Medical Innovation Award.

KEY PUBLICATIONS

1. Chen W, et al. Intra-arterial Alteplase Thrombolysis After Successful Thrombectomy for AIS in the Posterior Circulation: The IAT-TOP Randomized Clinical Trial. JAMA Neurol. 2026 Apr 24:e261074.
2. Li W, Lan J, et al. Normobaric hyperoxia combined with endovascular treatment for acute ischaemic stroke in China (OPENS-2 trial): a multicentre, randomised, single-blind, sham-controlled trial. The Lancet. 2025 Feb 8;405(10477):486-497.
3. Hou C, et al. Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis (the RICA trial): a multicentre, randomised, double-blind sham-controlled trial in China. Lancet Neurology. 2022 Dec;21(12):1089-1098.
4. Jovin TG, et al. Trial of Thrombectomy 6 to 24 Hours after Stroke Due to Basilar-Artery Occlusion. New England Journal of Medicine. 2022 Oct 12; 387(15): 1373-1384.
5. Hayakawa K, et al. Transfer of mitochondria from astrocytes to neurons after stroke. Nature. 2016 Jul 28;535(7613):551-5.

SHUYANG ZHANG

Professor, Chief Physician
President of Peking Union Medical College Hospital (PUMCH)
Vice President of the CAMS PUMC

Prof. Shuyang Zhang is President of Peking Union Medical College Hospital (PUMCH) and Vice President of Peking Union Medical College. A distinguished cardiologist, physician-scientist, educator, and healthcare leader, she is the first female president in the hospital's 100-year history. Under her leadership, PUMCH—widely recognized as one of China's top hospitals—has advanced a patient-centered model and high-quality institutional development, positioning her as an influential role model for the next generation of medical professionals, particularly women.Prof. Zhang's clinical and research expertise includes:

1. Multidisciplinary diagnosis and management of rare diseases, including genetic testing and counseling.
2. Comprehensive management and prevention of coronary heart disease, hypertension, dyslipidemia, diabetes, and metabolic syndrome, with a focus on reducing cardiovascular events and improving quality of life.
3. Evidence-based interventional diagnosis and treatment of coronary and peripheral vascular diseases.
4. Early diagnosis and individualized management of heart failure due to cardiomyopathies and other etiologies.
5. Management of complex, severe, and critically ill cases involving cardiovascular and systemic diseases.

Prof. Zhang is a national leader in rare disease diagnosis, treatment, and policy in China. She serves as Chair of the National Expert Committee on Rare Diseases Clinical Care and Accessibility, and has led the establishment of China's rare disease diagnosis and treatment framework.

Her work spans clinical innovation, translational research—including drug development—and large-scale system building. She has driven international collaboration in rare diseases, contributing to global strategy development through the International Rare Diseases Research Consortium (IRDiRC) and partnerships with Orphanet.

She led the development of PUMCH's pioneering postdoctoral residency program, designed to cultivate physician-scientists and academic leaders. She also founded and leads the China Consortium of Elite Teaching Hospitals, advancing graduate medical education standards and faculty development through international collaboration.

Prof. Zhang serves as China's representative to the World Medical Association and is a recipient of the Distinguished Service Award from the American College of Cardiology.

KEY PUBLICATIONS

1. Chen R, et al. Trends in rare disease drug development. Nat Rev Drug Discov. 2024 Mar; 23(3):168-169.
2. Yin W, et al. Structural basis for inhibition of SARS-CoV-2 RNA-dependent RNA polymerase by remdesivir. Science. 2020 Jun 26; 368(6498):1499-1504.
3. Zhang Y, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020 Apr 23; 382(17):e38.
4. Zhang S, et al. Orphan drug development in China: progress and challenges. Lancet. 2019 Sep 28; 394(10204):1127-1128.
5. Jing ZC, et al. Management of acute myocardial infarction during the COVID-19 outbreak. Eur Heart J. 2020 May 14;41(19):1791–1794.

TAO CHENG

President and Professor
Institute of Hematology & Blood Diseases Hospital
Academician of the Chinese Academy of Engineering

Prof. Cheng has performed seminal studies on the molecular basis of hematopoietic stem and progenitor cells (HSPC) in cell cycle control, radioprotection, bystander effects, and leukemic transformation, yielding therapeutic insights with clinical applications. He initiated and led the Atlas of Blood Cells (ABC) program, significantly shaping the field of single-cell transcriptomics of murine and human blood cells in both homeostatic and pathological conditions, with important implications for hematopoietic stem cell transplantation and regenerative medicine. Prof. Cheng has published more than 310 research articles, invited reviews and book chapters in leading journals including Science, Nature, Nature Medicine, Nature Genetics, Nature Cell Biology, Cell Stem Cell, and Blood, with H-factor 71. He is a holder of 38 granted patents.

He has established a comprehensive translational platform for cell and gene therapies in China, through which many cellular and gene therapy INDs have been granted. He also founded the Department of Stem Cells & Regenerative Medicine and its graduate program at Peking Union Medical College. He is the founding Chief Editor of Blood Science and the founding President of the Chinese Association for Blood Sciences (CABS).

He has received several prestigious awards, including the Junior Scholar Award from the American Society of Hematology, the Outstanding Scholar Award from the National Natural Science Foundation of China, the Chang-Jiang Scholar Award, the Scholar Award from the Leukemia and Lymphoma Society of USA, the Distinguished Professorship Award from China Medical Board, the Wu Jieping - Paul Janssen Medical & Pharmaceutical Award, and the Saint-Antoine-EBMT Achievement Award. He has served on the editorial boards of Blood, Leukemia, Stem Cells and others, and was twice elected as a board director of ISEH.

KEY PUBLICATIONS

1. Cheng T, et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science. 2000 Mar 10;287(5459):1804-8.
2. Cheng T, et al. Stem cell repopulation efficiency but not pool size is governed by p27(kip1). Nat Med. 2000 Nov;6(11):1235-40.
3. Yuan Y, et al. In vivo self-renewing divisions of haematopoietic stem cells are increased in the absence of the early G1-phase inhibitor, p18INK4C. Nat Cell Biol. 2004 May;6(5):436-42.
4. Yu H, et al. Hematopoietic stem cell exhaustion impacted by p18 and p21 in opposite manners. Blood. 2006 Feb 1;107(3):1200-6.
5. Zheng Z, et al. Uncovering the emergence of HSCs in the human fetal bone marrow by single cell RNA-seq analysis. Cell Stem Cell. 2022 Nov 3;29(11):1562-1579.e7.

DEPEI LIU

Professor of Institute of Basic Medical Sciences
Academician of Chinese Academy of Engineering

Prof. De-Pei Liu, Member of Chinese Academy of Engineering (CAE). Member of National Academy of Medicine (NAM), USA, and The Third World Academy of Sciences (TWAS). Co-Chair of InterAcademy Partnership for Health (IAPH). Principle Investigator and Laboratory Head. Ph. D. (1986, CAMS & PUMC).

The laboratory is mainly interested in functional genomics and gene regulatory network, molecular mechanisms underlying cardiovascular diseases, and targeted gene repair.

SCI papers published by the lab have exceeded 200, which have been cited over 12000 times.

KEY PUBLICATIONS

1. Zhang P, *et al.* Schlafen 11 triggers innate immune responses through its ribonuclease activity upon detection of single-stranded DNA. *Sci Immunol.* 2024 Jun 14;9(96):eadj5465.
2. Pei JF, *et al.* Diurnal oscillations of endogenous H_2O_2 sustained by $p66^{Shc}$ regulate circadian clocks. *Nat Cell Biol.* 2019 Dec;21(12):1553-1564.
3. Luo YX, *et al.* SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity. *Eur Heart J.* 2017 May 7;38(18):1389-1398.
4. Chen HZ, *et al.* Age-Associated Sirtuin 1 Reduction in Vascular Smooth Muscle Links Vascular Senescence and Inflammation to Abdominal Aortic Aneurysm. *Circ Res.* 2016 Oct 28;119(10):1076-1088.
5. Liu Y, *et al.* Calorie restriction protects against experimental abdominal aortic aneurysms in mice. *J Exp Med.* 2016 Oct 17;213(11):2473-2488.



ZHUANG TIAN

Professor and Doctoral Supervisor
Director of International Medical Services (IMS)
Chief Physician in Cardiology,
Peking Union Medical College Hospital (PUMCH)

Prof. Tian graduated from Peking Union Medical College in 1999 with an MD and has since worked in the Department of Internal Medicine and Cardiology at PUMCH. She has undertaken advanced clinical training at the University of California, San Francisco, and Johns Hopkins Hospital in the United States. She currently leads the IMS Department, which provides international-standard, high-quality healthcare services to foreign dignitaries, embassy personnel, senior executives, international visitors, and domestic patients.

Her clinical and research interests focus on heart failure, cardiomyopathy, and pulmonary hypertension, with particular expertise in cardiovascular imaging, including echocardiography. She has led and participated in more than 10 national and provincial research projects and has published over 120 peer-reviewed articles.

Prof. Tian is an active member of several professional societies, including the Chinese Society of Rare Diseases and the Chinese Society of Clinical Pharmacy, and serves as Secretary of the Heart Failure Group of the Chinese Society of Cardiology.

KEY PUBLICATIONS

1. Zhang Y, *et al.* CCL17 acts as a novel therapeutic target in pathological cardiac hypertrophy and heart failure. *J Exp Med.* 2022 Aug 1;219(8):e20200418.
2. Tian Z, *et al.* Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial. *JAMA Cardiol.* 2023 Oct 1;8(10):957-965.
3. Shen K, *et al.* Chinese consensus on the diagnosis and treatment of immunoglobulin light-chain cardiac amyloidosis. *Chin Med J (Engl).* 2024 Jan 20;137(2):127-129.
4. Lu Y, *et al.* Genetic landscape of hereditary cardiomyopathies and arrhythmias in China. *J Genet Genomics.* 2026 Feb;53(2):246-255.
5. Tian Z, *et al.* Long-Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER-CN Study. *J Am Heart Assoc.* 2026 Jun 2;15(11):e046251.

XIANGBIN PAN

Vice President, Professor
Structural Heart Disease Centre
Fuwai Hospital

Prof. Xiangbin Pan, FACC, FESC, MSTS, Deputy Director of the National Center for Cardiovascular Disease (NCCD), Vice President of Fuwai Hospital, and Director of the National Quality Control Center for Structural Heart Disease, is a hybrid cardiac physician holding dual licenses in open-heart surgery and percutaneous procedures. Prof. Pan invented and pioneered the world's first Percutaneous and Non-Fluoroscopic (PAN) Procedure for cardiovascular diseases, establishing international standards. Seventeen of his innovations have been recognized as world firsts, earning him the 2023 National Technology Invention Award and Patent Gold Award issued by the World Intellectual Property Organization and the China National Intellectual Property Administration.

The PAN Procedure employs ultrasound guidance to deliver devices via peripheral blood vessels for treating heart disease, requiring neither a surgical operating room nor a catheterization laboratory. *It* enables treatment without incisions, anesthesia, radiation, or contrast agents, transforming major heart surgeries into "doorstep surgeries". Twelve echo-guided automobile operating vehicles tour around the world to save lives, pioneering a new model of "doorstep surgeries".

Achieving world-leading standards in safety, efficacy, and accessibility, 23 products have been launched in China and the EU and deployed across 68 countries. Among these, the bioabsorbable occluder and echo guided wire (Panna wire) are the only globally available products of their kind. The United Nations, WHO, and IEEE officially designated this innovative technology system as the "PAN Procedure" in their documents.

Professor Xiangbin Pan was appointed as the Chief Technical Consultant by the United Nations. The technology received the WHO innovation award for its contribution to "reducing disparities in healthcare service capabilities among member states".

KEY PUBLICATIONS

1. Wang S, et al. Long-term thrombus-free left atrial appendage occlusion via magnetofluids. Nature. 2026 Mar; 651(8104):91-99.
2. Ouyang W, et al. Bioresorbable vs Metallic Occluders for Transcatheter Atrial Septal Defect Closure: A Randomized Clinical Trial. JAMA. 2025 Oct 23.
3. Zhang F, et al. Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial. Circulation. 2026 Jan 13;153(2):71-81.
4. Huang H, et al. Left Bundle Branch Pacing vs. Biventricular Pacing: mechanistic insights from dyssynchronous heart failure models. Eur Heart J. 2026 Apr 1;47(13):1595-1605.
5. An X, et al. Co-occurrence patterns and related risk factors of ischaemic heart disease and ischaemic stroke across 203 countries and territories: a spatial correspondence and systematic analysis. Lancet Glob Health. 2025 May;13(5):e808-e819.

ZHIHUA LIU

Vice President and Professor
Cancer Hospital

Prof. Liu obtained her Ph.D. in Biology from Peking University (1993) and finished post-doctoral studies in Washington State University. She joined the State Key Lab of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences since 1997, and currently she is a professor and director of the State Key Lab of Molecular Oncology, the vice president of Cancer Hospital CAMS.

Prof. Liu's research focuses on the molecular mechanism of esophageal cancer development as well as the translational study. The long-term goal is to understand the molecular mechanism of esophageal squamous cell carcinoma and develop new intervention strategies, find biomarkers for early detection, and build the clinically-relevant molecular classification for precision medicine of esophageal squamous cell carcinoma.

KEY PUBLICATIONS

1. Zhang Y, *et al.* Distinct cellular mechanisms underlie chemotherapies and their combinations with PD-L1 checkpoint inhibitor in triple-negative breast cancer. *Cancer Cell.* 2025 Mar 10;43(3):446-463.e7.
2. Pei X, *et al.* Single-cell multi-omic and spatial profiling of esophageal squamous cell carcinoma reveals the immunosuppressive role of GPR116+ pericytes in cancer metastasis. *Nat Genet*. 2025 Oct;57(10):2494-2508.
3. Liu Z, *et al.* Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. *Cancer Cell.* 2023 Jan 9;41(1):181-195.e9.
4. Zhang Y, *et al.* Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple negative breast cancer. *Cancer Cell.* 2021 Dec 13;39(12):1578-1593.e8.
5. Cui Y, *et al.* Whole genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma. *Cell Res.* 2020 Oct;30(10):902-913.

ZHONGJIE LI

Dean and Professor
School of Population Medicine and Public Health

Prof. Zhongjie Li is a Deputy Dean, Researcher, and Doctoral Supervisor at the School of Population Medicine and Public Health, CAMS & PUMC. Drawing on extensive experience in national-level disease prevention and control institute, he investigates infectious disease transmission dynamics, surveillance and early warning systems, disease burden assessment, and evaluation of intervention effectiveness.

As Principal Investigator, he has led major national projects, including the National Key R&D Program, the National Natural Science Foundation of China (NSFC), and the National Science and Technology Major Project. He has published over 100 peer-reviewed papers in leading Chinese and English professional journals, contributing to evidence-based public health policy and practice. He was awarded the 2024 National Science and Technology Progress Award (Second Prize).

KEY PUBLICATIONS

1. Li ZJ*, et al.* China CDC COVID-19 Emergency Response Strategy Team. Active case finding with case management: the key to tackling the COVID-19 pandemic*. Lancet.* 2020 Jul 4;396(10243):63-70.
2. Li ZJ, *et al.* Chinese Centers for Disease Control and Prevention (CDC) Etiology of Respiratory Infection Surveillance Study Team. Etiological and epidemiological features of acute respiratory infections in China, *Nature communications,* 2021, 12(1):5026.
3. Li ZJ, *et al.* Chinese Centers for Disease Control and Prevention (CDC) Etiology Surveillance Study Team of Acute Respiratory Infections. Broad Impacts of Coronavirus Disease 2019 (COVID-19) Pandemic on Acute Respiratory Infections in China: An Observational Study, *Clinical Infectious Diseases,* 2022, 75(1):e1054-e1062.
4. Liu YN, *et al.* Chinese Center for Disease Control and Prevention Etiology Surveillance Study Team of Acute Respiratory Infections. Infection and co-infection patterns of community-acquired pneumonia in patients of different ages in China from 2009 to 2020: a national surveillance study, Lancet Microbe, 2023, 4(5):e330-e339.
5. Ye CC, *et al.* Changes in Epidemics of Respiratory Viral Infections Resulted From the COVID-19 Pandemic in Shanghai, *Journal of Medical Virology,* 2024, 96(11):e70034.

YUELONG SHU

Director and Professor
National Institute of Pathogen Biology

Prof. Yuelong Shu is Director of the National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College. He is a Fellow of the American Academy of Microbiology, a member of the first batch of "National Science and Technology Innovation Leaders", and a recipient of the "2014 Top Ten Scientific and Technological Innovators" award. He has also been awarded the National Science Fund for Distinguished Young Scholars and the China Youth Science and Technology Award. His other honors include the Grand Prize, First Prize, and Second Prize of the National Science and Technology Progress Award, Advanced Individual in the National Medical and Health System, National Innovation Award, and Public Health and Preventive Medicine Development Contribution Award. He currently serves as Chairman of the Asia-Pacific Alliance for the Control of Influenza (APACI).

Shu has long focused on influenza prevention and control research, and has made outstanding achievements in the discovery of new viruses, the development of detection reagents, and the pathogenesis of infection. Through the systematic establishment of new influenza detection and surveillance technology, it was found for the first time in the world that a variety of new avian influenza viruses such as H7N9, H5N6 and H10N8 can lead to human infection and death; The first successful development of pandemic H1N1 2019 and H7N9 avian influenza detection reagent; The origin, evolution and infection mechanism of H7N9 and other avian influenza viruses were clarified, which provided key scientific and technological support for the successful prevention and control of the epidemic in China. He has published about 200 papers in Science, Nature, NEJM, Lancet and other academic journals as a corresponding author. The research results were selected as one of the ‘China’s 100 most influential international academic papers in 2013’and ‘2023 Top Ten Scientific Advances in China’.

KEY PUBLICATIONS

1. Chen Y, *et al.* Rare variant MX1 alleles increase human susceptibility to zoonotic H7N9 influenza virus. *Science.* 2021 Aug 20; 373(6557):918-922.
2. Gao R, *et al.* Human infection with a novel avian-origin influenza A (H7N9) virus. *N Engl J Med.* 2013 May 16;368(20):1888-97.
3. Zhou J, *et al.* Biological features of novel avian influenza A (H7N9) virus. *Nature.* 2013 Jul 25;499(7459):500-3.
4. Zhu H, *et al.* Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs, Science (New York, NY). *Science.* 2013 Jul 12;341(6142):183-6.
5. Chen H, *et al.* Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. *Lancet.* 2014 Feb 22;383(9918):714-21.

YOUCHUN WANG

Director and Professor
Institute of Medical Biology

Prof. Youchun Wang, member of the Academic Advisory Committee of Chinese Academy of Medical Sciences, executive director of the Institute of Medical Biology, Chinese Academy of Medical Sciences, professor of Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC).

He also serves as the Chinese representative of the International Vaccine Institute (IVI) Global Council; chairman of Vaccine Committee of the Chinese Pharmacopoeia Commission, and vice chairman of Microbiology and Immunology Committee of the Chinese Medical Association, Biochemical and Biotechnological Pharmaceuticals Committee of the Chinese Pharmaceutical Association, Vaccine Engineering Commission of the Chinese Society of Biotechnology.

He received his MD degree in epidemiology from Peking Medical University (later known as Peking University Health Science Center, PKUHSC); and obtained his PhD degree in virology from University College London (UCL). He is engaged in the fields of medical virology, epidemiology, molecular biology, and research on the quality control methods of relevant products. In recent years, he mainly focuses on the construction of pseudoviruses for emerging viral infectious diseases and outbreaks of viral infectious diseases; and applied research concerning virus mutation, neutralizing antibodies, and drug screening and testing.

He published over 360 academic papers as the first or corresponding author, of which over 160 of them were published in SCI journals, including 3 in *Cell*, 4 in *Nature*, and 1 in *Science*.

As the primary contributor, he won a second prize in the National Prize for Progress in Science and Technology, two first prizes in Beijing Technological Progress Award, a first prize in Chinese Medical Science and Technology Award, a first prize from Chinese Preventive Medicine Association, the 18th Wu Jieping-Paul Janssen Medical & Pharmaceutical Award, the Special Contribution Award of China Pharmaceutical Development Award-Food and Drug Quality Testing Technology Award. Besides, he was awarded as an advanced individual in combating the COVID-19 pandemic in the national science and technology system. He has been consistently listed in a series of prestigious global academic rankings for consecutive years, including Elsevier Highly Cited Chinese Researchers, Clarivate Highly Cited Researchers, World's Top 2% Scientists and World's Top 100,000 Scientists.

KEY PUBLICATIONS

1. Li Q, *et al.* The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. *Cell.* 2020 Sep 3;182(5):1284-1294.e9.
2. Lv Z, *et al.* Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. *Science.*2020 Sep 18;369(6510):1505-1509.
3. Li Q, *et al.* SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. *Cell.* 2021 Apr 29;184(9):2362-2371.e9.
4. Cao Y, *et al.* Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. *Nature.* 2022 Feb;602(7898):657-663.
5. Cao Y, *et al.* Imprinted SARS-CoV-2 Humoral Immunity Induces Convergent Omicron RBD Evolution. *Nature.* 2023 Feb;614(7948):521-529.

XUEMEI LI

Director of the Department of Internal Medicine
Professor and Chief Physician
Peking Union Medical College Hospital,
Chinese Academy of Medical Sciences(CAMS)
Peking Union Medical College(PUMC)

Prof. Xuemei Li is the Director of the Department of Internal Medicine at Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences. She also serves as Professor, Chief Physician, and Doctoral and Postdoctoral Supervisor. She received her Bachelor of Medicine from the six-year English-language medical program at West China University of Medical Sciences in 1989, earned her Doctor of Medicine in Nephrology from Peking Union Medical College in 1996, and completed postdoctoral research training in nephrology at the National Institutes of Health (NIH) in the United States from 2003 to 2005. Since joining PUMCH in 1988, she has been engaged in clinical practice, medical education, and academic administration in internal medicine and nephrology.

Her research focuses on nephrology, including IgA nephropathy, acute kidney injury, chronic kidney disease, and dialysis-related complications. She has published scientific articles in top-tier peer-reviewed journals such as NEJM, and has led multiple national and municipal research projects funded by the Ministry of Science and Technology and the Beijing Natural Science Foundation. She has served as Vice President of the Chinese Society of Nephrology and President of the Nephrology Branch of Beijing Medical Association and has participated in drafting multiple national clinical guidelines and expert consensuses. She has supervised more than 30 doctoral students, master's students, and postdoctoral researchers.

KEY PUBLICATIONS

1. Zhao X, *et al.* Effect of on-demand immunosuppressive therapy on long-term outcomes in patients with immunoglobulin A nephropathy: A real-world cohort study. *Nephrol Ther.* 2026 Feb 17;21(7):565-577.
2. Gao Z, *et al.* miR-7213-5p-mediated suppression of CCL19 in fibroblast cells may attenuate lupus nephritis. *Clin Exp Med.* 2025 Nov 25;26(1):39..
3. Fan X, *et al.* BRI is an independent predictor of new-onset kidney stones in a non-diabetic population: a retrospective analysis. *Front Endocrinol (Lausanne)*. 2025 Oct 15;16:1686183.
4. Wang G, *et al.* Clinical and Experimental Insights into the Role of NETosis in IgA Nephropathy Pathogenesis. *Kidney Dis (Basel).* 2025 May 9;11(1):450-468.
5. Zheng K, *et al.* Combinatorial lipidomics and proteomics underscore erythrocyte lipid membrane aberrations in the development of adverse cardio-cerebrovascular complications in maintenance hemodialysis patients. *Redox Biol.* 2024 Dec;78:103389.

LIN KANG

Professor
Director, Department of Geriatrics
Peking Union Medical College Hospital (PUMCH)

Prof. Kang Lin, MD, is a Chief Physician and Doctoral Supervisor. She received her Bachelor's degree from Bethune Medical College, Jilin University, in 2003; her Master's degree from Peking Union Medical College (PUMC) in 2010; and her Doctoral degree from PUMC in 2016. Currently, she serves as Director of the Department of Geriatrics at Peking Union Medical College Hospital (PUMCH) and as a Standing Committee Member of Chinese Society of Geriatrics of Chinese Medical Association.

Her primary research interests centre on the assessment and intervention of geriatric syndromes—including malnutrition, frailty, and sarcopenia—as well as the integrated management of geriatric comorbidities and perioperative care in older adults. Over the past five years, as Principal Investigator, she has led more than ten nationally funded and other tiered scientific research projects. She spearheaded the development of the "Intelligent Assessment and Intervention System for Frailty and Sarcopenia," which has obtained Class II medical device registration and successfully translated research findings into clinical practice. Dr. Kang has authored or co-authored over 100 peer-reviewed academic publications, contributed to the drafting of multiple domestic clinical consensus statements and practice guidelines, and participated in the formulation of national industry standards. In the past five years, she has been honoured with over 50 awards recognizing excellence in scientific research and medical education. Additionally, she serves as Course Director for the PUMC Clinical Medicine Pilot Program and as Chairperson of several national continuing medical education initiatives. She also oversees the WeChat official account "Heyannuan" of the Department of Geriatrics at PUMCH.

KEY PUBLICATIONS

1. Li Y, *et al.* Validation and Comparison of Four MortalityPrediction Models in a Geriatric Ward in China.Clinical Interventions in Aging. *Clin Interv Aging.* 2023 Nov 30:18:2009-2019.
2. Liu S, *et al.* Intrinsic Capacity predicts adverse outcomes using Integrated Care for Older People screening tool in a senior community in Beijing. *Arch Gerontol Geriatr.* 2021 May-Jun:94:104358.
3. Kang L, *et al.* Alterations in intestinal microbiota diversity, composition, and function in patients with sarcopenia. *Sci Rep.* 2021 Feb 25;11(1):4628.
4. Liu S, *et al.* Trajectory and Correlation of Intrinsic Capacity and Frailty in a Beijing Elderly Community. *Front Med (Lausanne).* 2021 Dec 9:8:751586.
5. Kang L, *et al.* Attitudes toward advance directives among patients and their family members in China. *J Am Med Dir Assoc*. 2017 Sep 1;18(9):808.e7-808.e11.

CAMS OXFORD INSTITUTE
HEALTHY AGEING SYMPOSIUM

OXFORD UK
JUNE 2026